Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11638377 | 0.98 | FAAH (0.50) | NAAALMNAHPGDFAAHALDH1A1 | |
| SCHEMBL11543795 | 0.94 | LMNA (0.53) | NAAALMNAHPGDALDH1A1FFAR1 | |
| SCHEMBL10327290 | 0.89 | LTA4H (0.46) | NAAALMNAFAAHALDH1A1FFAR1 | |
| SCHEMBL409318 | 0.86 | ALDH1A1 (0.63) | LMNAHPGDALDH1A1FFAR1MAPT | |
| SCHEMBL414487 | 0.82 | MAPT (0.66) | NAAALMNAFFAR1HSD17B10MAPT | |
| SCHEMBL1478337 | 0.82 | NAAA (0.51) | NAAALMNAHPGDFAAHFFAR1 | |
| SCHEMBL2565118 | 0.82 | ACHE (0.57) | NAAALMNAFAAHALDH1A1HSD17B10 | |
| SCHEMBL22526060 | 0.82 | FAAH (0.62) | LMNAHPGDFAAHALDH1A1HSD17B10 | |
| SCHEMBL22525361 | 0.82 | FAAH (0.53) | LMNAHPGDFAAHALDH1A1HSD17B10 | |
| SCHEMBL5541443 | 0.82 | ALDH1A1 (0.48) | HPGDFAAHALDH1A1HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316064-B2 | Teicoplanin analogs and uses thereof | ACADEMIA SINICA (TW) | 2019-06-11 | — | — | US | disclosed |
| US-20170327542-A9 | TEICOPLANIN ANALOGS AND USES THEREOF | ACADEMIA SINICA (TW) | 2017-11-16 | — | — | US | disclosed |
| US-20160347795-A1 | TEICOPLANIN ANALOGS AND USES THEREOF | ACADEMIA SINICA (TW) | 2016-12-01 | — | — | US | disclosed |
| US-20130295261-A1 | ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS | SENOMYX, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-8420145-B2 | Isosorbide derivatives and their use as flavor modifiers, tastants, and taste enhancers | SENOMYX, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20090220662-A1 | ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS | SENOMYX, INC. | 2009-09-03 | — | — | US | disclosed |
| US-4160036-A | ADRENERGIC STIMULANTS | ALLEN & HANBURYS LIMITED (GB) | 1979-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220662-A1 | ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS | TAS2R10, TAS2R41, TAS2R30 | NAAA 2059/4885LMNA 4323/4885HPGD 2593/4885 |
| US-10316064-B2 | Teicoplanin analogs and uses thereof | NGLY1, VIP, NRDC | NAAA 430/4885LMNA 2232/4885HPGD 665/4885 |
| US-20170327542-A9 | TEICOPLANIN ANALOGS AND USES THEREOF | NGLY1, VIP, NRDC | NAAA 393/4885LMNA 2416/4885HPGD 669/4885 |
| US-20160347795-A1 | TEICOPLANIN ANALOGS AND USES THEREOF | NGLY1, VIP, NRDC | NAAA 393/4885LMNA 2416/4885HPGD 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.